Development of Medical Countermeasures for COVID-19

制定针对 COVID-19 的医疗对策

• 批准号: 10854680
• 负责人: RAYMOND TAYLOR
• 金额: $ 44.08万
• 依托单位: BIOCRYST PHARMACEUTICALS, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-11 至 2022-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10854680
• 关键词: 2019-nCoV; Advanced Development; COVID-19; COVID-19 therapeutics; Development; Support Contracts; medical countermeasure; pre-clinical; product development; research and development; therapeutic candidate; therapeutic development

This contract supports the advanced development of promising therapeutic candidates with broad spectrum activity. The research and development activities to be supported will allow candidate therapeutic products to progress through the product development pipeline, and includes preclinical and non-clinical activities, as well as IND development activities.

该合同支持具有广谱活性的有前途的治疗候选药物的先进开发。支持的研发活动将允许候选治疗产品通过产品开发管道进行，包括临床前和非临床活动，以及IND开发活动。